1. Figure 2. A consort diagram showing the flowchart of the trial
Figure 2. A consort diagram showing the flowchart of the trial. DFS = disease-free survival; IC = informed consent; ITT = intention to treat.
From: Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG )
J Natl Cancer Inst. 2017;110(1). doi: /jnci/djx134
J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please

2. Figure 1. An overview of the trial design.
From: Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG )
J Natl Cancer Inst. 2017;110(1). doi: /jnci/djx134
J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please

3. Figure 3. A plot showing the number of patients on therapy (y-axis) for each timepoint (x-axis), stratified by treatment arm.
From: Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG )
J Natl Cancer Inst. 2017;110(1). doi: /jnci/djx134
J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please

4. Figure 4. Kaplan-Meier analysis
Figure 4. Kaplan-Meier analysis. Results are shown for (A) disease-free survival, (B) overall survival, (C) distant metastasis–free interval, and (D) new primary breast cancer, including all randomly assigned patients based on intention-to-treat principle. Log-rank tests were used to assess the differences between groups within each graph (reported as P values).
From: Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG )
J Natl Cancer Inst. 2017;110(1). doi: /jnci/djx134
J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please

5. Figure 5. A preplanned subgroup analysis
Figure 5. A preplanned subgroup analysis. All values were determined using two-sided Cox regression analysis. Error bars represent 95% confidence intervals. AI = aromatase inhibitor; CI = confidence interval; HR = hazard ratio; HT = hormonal therapy; PgR = progesterone receptor; T size = tumor size; tam = tamoxifen.
From: Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG )
J Natl Cancer Inst. 2017;110(1). doi: /jnci/djx134
J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please

6. Figure 6. Secondary analysis
Figure 6. Secondary analysis. Results are shown for (A) disease-free survival, (B) overall survival, (C) distant metastasis–free interval, and (D) new primary breast cancer, including all patients who were disease free and on therapy at 2.25 years. Log-rank tests were used to assess the differences between groups within each graph (reported as P values).
From: Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG )
J Natl Cancer Inst. 2017;110(1). doi: /jnci/djx134
J Natl Cancer Inst | © The Author Published by Oxford University Press. All rights reserved. For Permissions, please